Cardiomyopathy, Congenital Heart Disease, Pulmonary Arterial Hypertension, SARS CoV-2 Infection
Conditions
Brief summary
The goal of this observational study, drug-free, cross-sectional, single-center is to describe the incidence and characteristics of the clinical course and any short- and medium-term complications of patients with congenital heart disease of medical interest, and pediatric patients with cardiomyopathy, arrhythmic pathology or pulmonary arterial hypertension who have been affected by Sars-Cov-2 disease. The secondary objective of the study is to identify risk factors for the development of moderate-severe forms of COVID-19 disease in the study population.
Detailed description
This is an observational, drug-free, cross-sectional, single-centre study. All patients followed at our centre and suffering from congenital heart disease treated with only haemodynamic procedures haemodynamic procedures alone, as well as paediatric patients suffering from cardiomyopathy, pulmonary hypertension or arrhythmic pathology whose follow-up was still in progress at the time of the start of the pandemic (due to death or for reasonsof the patient). The structural collection of data necessary for the evaluation of targets will take place through the creation of a specific electronic archive, in which census of all patients who have undergone follow-up at our centre since 01/01/2005 at the time of study approval and still in follow-up at the time of the start of the pandemic. Patients of all ages will be enrolled age, both paediatric and adult, followed at our centre. It is estimated to include in the study approximately 5000 patients.
Interventions
None listed
Sponsors
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Inclusion criteria
* Patients of all ages with congenital heart disease undergoing hemodynamic procedures at our center or in natural history * Pediatric patients with cardiomyopathy, arrhythmic disease, or hypertension pulmonary * Obtaining informed consent * Patients who have access to an e-mail address and a computer to complete the questionnaire
Exclusion criteria
* Patients with congenital heart disease undergoing corrective or palliative surgical treatment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Severity of SARS-CoV-2 infection evaluation | Upon completion of the questionnaire by patient on day 1 | The presence of ongoing SARS-CoV-2 infection will be defined as detection of viral RNA to a molecular swab or the detection of specific antigen at an antigenic swab, while the presence of previous infection will be defined as the presence of seroconversion for SARS-CoV-2 at a quantitative serological test. Severity of SARS-CoV-2 infection will be defined at different forms: * Severe form: Admission to intensive care unit, need for invasive respiratory support, death * Moderate form: Need for hospitalization or home oxygen therapy, or Worsening of oxygen dependence in patients on chronic home oxygen therapy. * Mild form: Symptomatic patients who do not meet the criteria for moderate or severe disease. * Asymptomatic form: Patients with infection positivity who do not have symptoms of disease. The patients' medical history and clinical data, as reported in the questionnaire, will be evaluated to look for possible risk factors for the development of severe forms of COVID-19 disease. |
Countries
Italy
Outcome results
None listed